Prolactin stimulation of phosphoinositide metabolism in CHO cells stably expressing the PRL receptor.

Biochem Biophys Res Commun

Laboratoire de Neurophysiologie UMR 5543, Bordeaux, France.

Published: February 1998

PRL receptor (PRL-R) activation by PRL triggers a cascade of intracellular events including homodimerization of the receptor, activation of cytoplasmic receptor-associated tyrosine kinase and tyrosine-phosphorylation of various signal transducers. In CHO cells, transfected with the long form of PRL-R, an increase in [Ca2+]i was observed following PRL stimulation whereas Ca2+ is generally coupled with the phosphoinositide metabolism. In this study, we investigated phosphoinositide involvement in the PRL transduction pathway. We report that PRL induces rapid increases in two novel inositol phospholipids, almost certainly PtdIns(4,5)P2 and PtdIns(3,4,5)P3. Pre-traitment of CHO cells with wortmanin, a specific PtdIns3-kinase inhibitor, considerably reduces the PRL-induced increase in PtdInd(3,4,5)P3, thus suggesting an involvement of this enzyme in the cascade of activation of cytoplasmic kinase proteins. A pathway beginning with the activation of PtdIns3-kinase, phosphorylation of PtdIns(4,5)P2 and rapid synthesis of PtdIns(3,4,5)P3 is proposed. PtIns(3,4,5)P3 may acts as a lipid second messenger, directly or indirectly responsible for some of the multiple cell changes attributed to PRL.

Download full-text PDF

Source
http://dx.doi.org/10.1006/bbrc.1997.7978DOI Listing

Publication Analysis

Top Keywords

cho cells
12
phosphoinositide metabolism
8
prl receptor
8
activation cytoplasmic
8
prl
7
prolactin stimulation
4
stimulation phosphoinositide
4
metabolism cho
4
cells stably
4
stably expressing
4

Similar Publications

ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip.

Nat Genet

January 2025

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Transcription factors are frequent cancer driver genes, exhibiting noted specificity based on the precise cell of origin. We demonstrate that ZIC1 exhibits loss-of-function (LOF) somatic events in group 4 (G4) medulloblastoma through recurrent point mutations, subchromosomal deletions and mono-allelic epigenetic repression (60% of G4 medulloblastoma). In contrast, highly similar SHH medulloblastoma exhibits distinct and diametrically opposed gain-of-function mutations and copy number gains (20% of SHH medulloblastoma).

View Article and Find Full Text PDF

The tumor microenvironment characterized by heterogeneously organized vasculatures causes intra-tumoral heterogeneity of oxygen partial pressure at the cellular level, which cannot be measured by current imaging techniques. The intra-tumoral cellular heterogeneity may lead to a reduction of therapeutic effects of radiation. The purpose of this study was to investigate the effects of the heterogeneity on biological effectiveness of H-, He-, C-, O-, and Ne-ion beams for different oxygenation levels, prescribed dose levels, and cell types.

View Article and Find Full Text PDF

Sex differences in the outcomes of advanced renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICIs) and the profiles of tumor-infiltrating immune cells (TIICs) remain unclear. We retrospectively evaluated data from 563 patients with RCC receiving systemic therapy, including first-line dual ICI combinations (i.e.

View Article and Find Full Text PDF

Diversity in Notch ligand-receptor signaling interactions.

Elife

January 2025

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, United States.

The Notch signaling pathway uses families of ligands and receptors to transmit signals to nearby cells. These components are expressed in diverse combinations in different cell types, interact in a many-to-many fashion, both within the same cell (in cis) and between cells (in trans), and their interactions are modulated by Fringe glycosyltransferases. A fundamental question is how the strength of Notch signaling depends on which pathway components are expressed, at what levels, and in which cells.

View Article and Find Full Text PDF

Background: Beta-2 microglobulin (β2m) is a component of the major histocompatibility complex class I (MHC-I) playing a crucial role in the immune system on cell surface, but it can be separated from the MHC-I and exist in biological fluid independently. Numerous reports have shown that β2m is a systemic pro-aging factor impairing cognitive function, and that it is increased in the blood and CSF of patients with Alzheimer's disease (AD). While β2m in the body fluid has been recognized as a potential factor in AD and aging, the development of therapeutic agents, especially those directly targeting β2m using antibodies, may face challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!